Inklusionskriterier:	Ja	Nej
Immunocompetent patients with newly-diagnosed primary central nervous system B-cell lymphoma		
Age 18-65 years irrespective of ECOG or 66-70 years (with ECOG Performance Status ≤ 2)		
Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy		
Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy		
Disease exclusively located in the CNS		
At least one measurable lesion		
Previously untreated patients (previous or ongoing steroid treatment admitted)		
Sexually active patients of childbearing potential who agree to take adequate contraceptive measures during study participation		
Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease		

Eksklusionskriterier:	Ja	Nej
Congenital or acquired immunodeficiency		
Systemic lymphoma manifestation (outside the CNS)		
Isolated ocular lymphoma without manifestation in the brain parenchyma or spinal cord		
Previous or concurrent malignancies with the exception of surgically cured carcinoma insitu of the cervix, carcinoma of the skin or other kinds of cancer without evidence ofdisease for at least 5 years		
Previous Non-Hodgkin lymphoma at any time		
Inadequate bone marrow (platelet count decreased ≥CTC grade 1, anemia ≥CTC grade 1, neutrophil count decreased ≥CTC grade 1), renal (creatinine clearance < 60 ml/min), cardiac (ejection fraction decreased ≥CTC grade 2), or hepatic function (blood bilirubin increased ≥CTC grade 2, alanine aminotransferase increased ≥CTC grade 2, aspartate aminotransferase increased ≥CTC grade 2 or gamma-GT increased ≥CTC grade 2)		
HBsAg, anti-HBc or HCV positivity		
HIV infection, previous organ transplantation or other clinical evident form of immunodeficiency		
Concurrent treatment with other experimental drugs or participation in a clinical trial within the last thirty days before study inclusion		
Symptomatic coronary artery disease, cardiac arrhythmias uncontrolled with medication or myocardial infarction within the last 6 months (New York Heart Association Class III or IV heart disease)		
Severe non-compensated pulmonary disease (IVC <55%, DLCO <40%)		
Third space fluid accumulation > 500 ml		
Hypersensitivity to study treatment or any component of the formulation		
Taking any medications likely to cause interactions with the study medication		
Known or persistent abuse of medication, drugs or alcohol		
Patient without legal capacity and who is unable to understand the nature, significance and consequences of the study and without designated legal representative		
Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator		
Any familial, sociological or geographical condition potentially hampering compli-		

Eksklusionskriterier:	Ja	Nej
Compliance with the study protocol and follow-up schedule		
Concurrent (or planned) pregnancy or lactation		
Fertile patients refusing to use safe contraceptive methods during the study		

Dato: ___/___ 20__ Læge (underskrift): _____ Læge (init): _____